Novo Nordisk halts cell therapy work for diabetes as part of cost cuts
NegativeFinancial Markets

Novo Nordisk has decided to halt its cell therapy research aimed at treating diabetes as part of a broader cost-cutting strategy. This decision is significant as it reflects the challenges pharmaceutical companies face in balancing innovation with financial sustainability. The cessation of this promising research could delay advancements in diabetes treatment, impacting patients who rely on new therapies for better management of their condition.
— Curated by the World Pulse Now AI Editorial System